38,069 0%
Subscribing Stocktwits Users

Sign up to access historical data

Sign up

Month over Month

Subscribing Stocktwits Users

Oct 2024 37,769
Sep 2024 37,740
Aug 2024 37,697
Jul 2024 37,629
Jun 2024 37,601

How many users are following Crispr Therapeutics on StockTwits?

The interest in Crispr Therapeutics on StockTwits is decent, with a following of 33,936 investors.

Analyzing Stocktwits Subscribers, how is Crispr Therapeutics performing compared to its industry peers?

Crispr Therapeutics underperforms its industry peers when it comes to Stocktwits Subscribers, ranking in the 25th percentile.

What has been the change in Crispr Therapeutics' StockTwits followers over the past month?

The number of followers for Crispr Therapeutics on StockTwits has risen by 0.8% in the last month, indicating a growing interest or optimism among investors. For investors, this upward trend in follower count is an important indicator to consider, as it may reflect broader market sentiments and could have implications for Crispr Therapeutics' price performance.

What is StockTwits?

StockTwits is a social media platform designed specifically for the investing community. It enables investors and traders to share market insights, strategies, and real-time news updates. Essentially, it's a specialized network for financial market discussions, often characterized by brief, tweet-like posts.

Why is it important for Crispr Therapeutics investors to monitor its StockTwits followers?

For investors in Crispr Therapeutics, tracking the number of followers on StockTwits can be highly beneficial. The platform's follower count offers a direct gauge of investor interest and sentiment surrounding Ford. An increasing follower count typically suggests growing investor attention and can be an indicator of rising market enthusiasm or concern about the company's prospects. This data can provide investors with valuable insights into market trends, potential shifts in investor behavior, and broader perceptions of Ford in the investment community.

Sign up and get more insights on Crispr Therapeutics.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.